HOPE At Heart (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System.

Last updated: November 26, 2024
Sponsor: XVIVO Perfusion
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congestive Heart Failure

Chest Pain

Heart Failure

Treatment

XVIVO Heart Assist Transport System

Clinical Study ID

NCT06485596
HOPE at Heart
  • Ages > 18
  • All Genders

Study Summary

The purpose of the clinical investigation is to support the use of direct procurement of donor hearts in donation after circulatory death followed by hypothermic oxygenated perfusion using the XVIVO Heart Assist Transport System. Thereby increasing the utilization of DCD donor hearts in donation after circulatory death.

The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System.

The secondary objectives are to evaluate patient outcomes and graft function post-transplant.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years

  2. Signed informed consent form

  3. Accepted and/or listed for heart transplantation

Exclusion

Exclusion Criteria:

  1. Not able to understand the information provided during the informed consentprocedure

  2. Previous solid organ transplantation

  3. Grown-up congenital heart disease

  4. Dialysis

  5. Incompatible blood group

  6. Combined organ transplantation candidates

  7. Subjects under pre-transplant desensitization protocol (including plasma exchange inconjunction with the transplant surgery)

  8. Mechanical circulatory support pre-transplantation (except durable Left ventricularassist device or Intra-aortic balloon pump)

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: XVIVO Heart Assist Transport System
Phase:
Study Start date:
August 03, 2024
Estimated Completion Date:
June 30, 2026

Study Description

This is a prospective, single-arm, multi-national, multicentre, proof-of-concept study to evaluate post-transplant outcomes after the use of direct procurement followed by a period of hypothermic oxygenated perfusion of the donor heart in DCD using the XVIVO Heart Assist Transport system.

The investigation will be conducted at 4 heart transplant centres, one in Belgium and three in The Netherlands.The study will include 20 DCD heart transplant recipients and will evaluate transplant outcomes such as post-transplant complications, patient survival and graft function for a period of 6 months post-transplant.

The study will not include a control group as this is a proof-of-concept study, investigating an alternative method of procurement of DCD hearts by providing additional safety and performance data.

The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System.

The secondary objectives are to evaluate patient outcomes and graft function post-transplant.

Connect with a study center

  • UZ Leuven

    Leuven,
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.